Abbott Laboratories ($ABT) is a global healthcare leader with a diverse portfolio spanning diagnostics, medical devices, nutritionals, and established pharmaceuticals. Its broad reach and innovation-driven approach place it at the center of the competitive medical technology and healthcare landscape. Abbott faces competition from a range of companies, from highly specialized device makers to diversified healthcare conglomerates. Below, we explore Abbott’s key competitors and peers, their product lines, and how they stack up against Abbott.
Key Competitors and Peers of Abbott Laboratories
- Edwards Lifesciences Corp ($EW**)**
- Becton Dickinson & Co ($BDX**)**
- Boston Scientific Corp ($BSX**)**
- Danaher Corp ($DHR**)**
- Stryker Corp ($SYK**)**
- Medtronic plc ($MDT**)**
- Zimmer Biomet Holdings Inc ($ZBH**)**
- Intuitive Surgical Inc ($ISRG**)**
- Johnson & Johnson ($JNJ**)**
- Thermo Fisher Scientific Inc ($TMO**)**
Comparison Table: Abbott and Its Competitors
| Ticker | Company Name | Market Cap | Subsector | Positioning vs. Abbott (if available) |
|---|---|---|---|---|
| $ABT | Abbott Laboratories | $147.13B | Medical Devices | Baseline company. Identifies Edwards as a primary competitor in TAVR, TMTT, and Surgical. |
| $EW | Edwards Lifesciences Corp | $46.86B | Medical Devices | Direct competitor in structural heart (TAVR, TMTT, Surgical). Abbott is named as a primary competitor. |
| $BDX | Becton Dickinson & Co | $39.53B | Medical Instruments & Supplies | No explicit comparison; broad-based in medtech and diagnostics/life sciences. |
| $BSX | Boston Scientific Corp | $78.30B | Medical Devices | No explicit comparison; product overlap in cardiac rhythm and interventional areas. |
| $DHR | Danaher Corp | $114.60B | Diagnostics & Research | No explicit comparison; more concentrated in life sciences/diagnostics/biotech tools. |
| $SYK | Stryker Corp | $117.60B | Medical Devices | No explicit comparison; not identified as a competitor to Abbott. |
| $MDT | Medtronic plc | $97.77B | Medical Devices | Direct overlap in diabetes and structural heart. Partnership with Abbott in CGM; both compete in cardiovascular categories. |
| $ZBH | Zimmer Biomet Holdings Inc | $16.19B | Medical Devices | No explicit comparison; not identified as a competitor to Abbott. |
| $ISRG | Intuitive Surgical Inc | $149.19B | Medical Instruments & Supplies | No explicit comparison; Abbott not named as a competitor. |
| $JNJ | Johnson & Johnson | $545.74B | Drug Manufacturers - General | No explicit comparison; Abbott not named as a competitor. |
| $TMO | Thermo Fisher Scientific Inc | $162.90B | Diagnostics & Research | No explicit comparison; more focused on tools, diagnostics, and services. |
Abbott vs. Edwards Lifesciences ($EW**)**
- Edwards Lifesciences is a direct competitor to Abbott in the structural heart space, specifically in transcatheter aortic valve replacement (TAVR), transcatheter mitral and tricuspid therapies (TMTT), and surgical heart valve therapies.
- Both companies are recognized as leading global competitors in these areas, with Edwards explicitly naming Abbott as a primary competitor in its filings.
Abbott vs. Medtronic ($MDT**)**
- Medtronic and Abbott overlap significantly in diabetes care (notably continuous glucose monitoring) and structural heart therapies.
- The two companies are both named as primary competitors by Edwards in TAVR and surgical heart valves.
- Medtronic also partners with Abbott to expand CGM options, indicating both competition and collaboration.
Abbott vs. Becton Dickinson ($BDX**)**
- BD is a broad-based medtech and diagnostics company, but there is no explicit mention of direct competition with Abbott in the filings.
- Both companies have diversified portfolios, but BD’s focus is more on medical instruments and supplies.
Abbott vs. Boston Scientific ($BSX**)**
- Boston Scientific operates in adjacent cardiac and interventional markets, but the filings do not explicitly position it against Abbott.
- There is likely competitive overlap in cardiac rhythm management and interventional oncology.
Abbott vs. Danaher ($DHR**)**
- Danaher is more concentrated in life sciences, diagnostics, and biotech tools, while Abbott’s portfolio includes nutrition and established pharmaceuticals.
- No explicit competitive positioning is provided in the filings.
Abbott vs. Stryker ($SYK**)**
- Stryker is a leader in orthopaedics, MedSurg, and neurotechnology, with no explicit competitive overlap with Abbott in the filings.
Abbott vs. Zimmer Biomet ($ZBH**)**
- Zimmer Biomet focuses on musculoskeletal care and orthopaedics, with no direct competitive positioning against Abbott.
Abbott vs. Intuitive Surgical ($ISRG**)**
- Intuitive Surgical is a leader in robotic-assisted surgery, with no explicit mention of Abbott as a competitor.
Abbott vs. Johnson & Johnson ($JNJ**)**
- J&J is a diversified healthcare giant with significant medtech and pharmaceutical operations, but Abbott is not named as a competitor in the filings.
Abbott vs. Thermo Fisher Scientific ($TMO**)**
- Thermo Fisher is focused on life sciences tools, diagnostics, and services, with no explicit comparison to Abbott.
Conclusion
Abbott Laboratories operates in a highly competitive environment, facing direct competition from companies like Edwards Lifesciences and Medtronic in structural heart and diabetes care. Other peers, such as Becton Dickinson, Boston Scientific, Danaher, Stryker, Zimmer Biomet, Intuitive Surgical, Johnson & Johnson, and Thermo Fisher Scientific, compete in adjacent or overlapping markets but are not always direct competitors across all product lines. Abbott’s broad portfolio and innovation-driven strategy ensure it remains a central player in the global healthcare landscape, with its competitive positioning varying by segment and geography.
